Impact of Antiplatelet and Anticoagulant Therapies on Platelet-related Prognostic Markers in Patients With Esophageal Cancer.
Esophageal cancer
platelet-to-lymphocyte ratio
prognostic factors
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
31
03
2020
revised:
08
04
2020
accepted:
10
04
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
In recent years, platelet-related markers were recognized as useful prognostic factors in various malignancies. We investigated the relationship between platelet-related prognostic markers and anti-platelet or anti-coagulant therapies for survival outcomes in esophageal squamous cell carcinoma. Preoperative platelet-related prognostic markers were evaluated from peripheral blood testing and statistical analyses were performed to evaluate the prognostic value of these markers and reveal the effects of antiplatelets and/or anticoagulants regarding their prognostic relevance. In all 176 patients, preoperative platelet-to-lymphocyte ratio (PLR) was not found to be a predictor of overall survival (OS). However, in patients without antiplatelet or anticoagulant therapies, PLR was significantly associated with a poor OS (p=0.03). Although platelet large cell ratio (P-LCR) was not associated with the prognosis in patients with antiplatelet and/or anticoagulant therapies, higher P-LCR was associated with a poor prognosis in patients without antiplatelet or anticoagulant therapies (p<0.0001). Researching detailed antiplatelet and anticoagulant therapies could reinforce the prognostic value of platelet-related prognostic markers in ESCC.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
In recent years, platelet-related markers were recognized as useful prognostic factors in various malignancies. We investigated the relationship between platelet-related prognostic markers and anti-platelet or anti-coagulant therapies for survival outcomes in esophageal squamous cell carcinoma.
PATIENTS AND METHODS
METHODS
Preoperative platelet-related prognostic markers were evaluated from peripheral blood testing and statistical analyses were performed to evaluate the prognostic value of these markers and reveal the effects of antiplatelets and/or anticoagulants regarding their prognostic relevance.
RESULTS
RESULTS
In all 176 patients, preoperative platelet-to-lymphocyte ratio (PLR) was not found to be a predictor of overall survival (OS). However, in patients without antiplatelet or anticoagulant therapies, PLR was significantly associated with a poor OS (p=0.03). Although platelet large cell ratio (P-LCR) was not associated with the prognosis in patients with antiplatelet and/or anticoagulant therapies, higher P-LCR was associated with a poor prognosis in patients without antiplatelet or anticoagulant therapies (p<0.0001).
CONCLUSION
CONCLUSIONS
Researching detailed antiplatelet and anticoagulant therapies could reinforce the prognostic value of platelet-related prognostic markers in ESCC.
Identifiants
pubmed: 32606166
pii: 34/4/1941
doi: 10.21873/invivo.11991
pmc: PMC7439896
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1941-1949Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Ann Surg Oncol. 2018 Oct;25(11):3288-3299
pubmed: 30019304
Sci Rep. 2019 Mar 8;9(1):3959
pubmed: 30850724
PLoS One. 2017 Dec 7;12(12):e0189166
pubmed: 29216259
Med Oncol. 2014 Dec;31(12):305
pubmed: 25355641
Asian Pac J Cancer Prev. 2015;16(6):2245-50
pubmed: 25824745
World J Surg. 2018 Jan;42(1):172-184
pubmed: 28744596
Ann Surg Oncol. 2011 Nov;18(12):3362-9
pubmed: 21547702
World J Surg Oncol. 2014 Mar 19;12:58
pubmed: 24641770
J Clin Invest. 2012 Jul;122(7):2661-71
pubmed: 22684106
BMC Cancer. 2015 May 02;15:350
pubmed: 25934640
J Cancer. 2018 Feb 12;9(5):807-815
pubmed: 29581759
Cardiol J. 2013;20(5):491-8
pubmed: 24469872
Anticancer Res. 2019 Oct;39(10):5675-5682
pubmed: 31570466
Oncotarget. 2017 Jun 19;8(40):68837-68846
pubmed: 28978160
Zhonghua Zhong Liu Za Zhi. 2014 Dec;36(12):910-5
pubmed: 25623765
Ann Gastroenterol Surg. 2019 Oct 21;4(1):56-63
pubmed: 32021959
JAMA. 2009 May 13;301(18):1909-19
pubmed: 19436018
World J Surg. 2010 Dec;34(12):2830-6
pubmed: 20703457
Virchows Arch. 2018 Apr;472(4):519-531
pubmed: 29209757
Oncotarget. 2017 Jul 18;8(29):48138-48144
pubmed: 28624815
Lancet. 2010 Nov 20;376(9754):1741-50
pubmed: 20970847
PLoS One. 2015 Sep 21;10(9):e0138657
pubmed: 26390126
J Cancer Res Clin Oncol. 2017 Oct;143(10):2077-2086
pubmed: 28601935
J Pharmacol Exp Ther. 2013 Jun;345(3):430-7
pubmed: 23536315
J Thromb Haemost. 2011 Feb;9(2):237-49
pubmed: 21040448
Cancer. 1995 Oct 1;76(7):1116-9
pubmed: 8630885
Surgery. 2012 May;151(5):667-73
pubmed: 22244180
Clin Exp Metastasis. 2010;27(1):25-34
pubmed: 19916050
Anticancer Res. 2016 Dec;36(12):6557-6562
pubmed: 27919983
JAMA. 2018 Nov 13;320(18):1857-1858
pubmed: 30193304
Br J Haematol. 2005 Mar;128(5):698-702
pubmed: 15725092
Onco Targets Ther. 2015 Apr 10;8:789-94
pubmed: 25914549
Ann Surg Oncol. 2012 Jan;19(1):68-74
pubmed: 21879261
Tumour Biol. 2016 Nov;37(11):14355-14361
pubmed: 27614687
Ann Oncol. 2000 Sep;11(9):1171-3
pubmed: 11061614